{"entity":{"id":"limertinib","kind":"drug","name":"Limertinib","aka":[],"tldr":"Limertinib is Aosaikang's third-generation EGFR inhibitor, approved in China in 2024 for lung cancer with the T790M resistance mutation after earlier EGFR drugs, and in phase 3 trials for first-line use.","summary":"Jiangsu Aosaikang's limertinib (ASK120067) was approved by the NMPA in 2024 for locally advanced or metastatic EGFR T790M-positive non-small cell lung cancer after progression on earlier EGFR inhibitors, joining osimertinib, furmonertinib and befotertinib among China's third-generation options. A phase 3 first-line trial against gefitinib is registered.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Limertinib","url":"https://clinicaltrials.gov/search?intr=ASK120067"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04143607"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, curated)","editedOn":"2026-09-16"},"code":"ASK120067","modality":"Oral third-generation EGFR tyrosine kinase inhibitor","mechanism":"A covalent inhibitor of EGFR sensitising and T790M resistance mutations that spares wild-type EGFR, the osimertinib class.","approvals":[{"region":"CN","year":2024,"indication":"Locally advanced or metastatic EGFR T790M-mutant non-small cell lung cancer after prior EGFR inhibitor therapy"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/limertinib/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"trial":[{"id":"nct04143607","kind":"trial","name":"ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC","route":"/trials/nct04143607/"},{"id":"nct07109531","kind":"trial","name":"ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy","route":"/trials/nct07109531/"}]}}